Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 17, 2026, by and among Lisata Therapeutics, Inc., a Delaware corporation (“Parent”), Mariner Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiar...
